Trial Profile
A Randomized Phase 2b/Phase 3 P201 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination with FOLFIRINOX Compared with FOLFIRINOX Alone as second-line therapy in Patients with Metastatic Pancreatic Cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Trabedersen (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Mateon Therapeutics; Oncotelic Therapeutics
- 23 Aug 2023 According to a Oncotelic Therapeutics media release, its joint venture partner, GMP Biotechnology's subsidiary, Sapu Bioscience and Cromos Pharma, are initiating the trial for OT-101 in Pancreatic Cancer.
- 16 May 2023 According to a Oncotelic Therapeutics media release, company will present ongoing advancement of clinical trials of OT-101 at 2023 BIO International Convention. Company's presentation is readily accessible at https://www.oncotelic.com/wp-content/uploads/2023/05/BIO-2023-V2.pdf
- 16 May 2023 According to a Oncotelic Therapeutics media release, trial for OT-101 in conjunction with P201 in Pancreatic Cancer is set to commence in the second half of 2023.